ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility
Citations
American Society of Hematology. (2021).
ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility.
Retrieved from https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-re-fda-draft-guidance-on-cancer-trial-eligibility.
American Society of Hematology.
"ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility." Hematology.org.
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-re-fda-draft-guidance-on-cancer-trial-eligibility
(label-accessed February 13, 2025).
"American Society of Hematology."
ASH Letter re FDA Draft Guidance on Cancer Trial Eligibility, 13 Feb. 2025 ,
https://www.hematology.org/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-re-fda-draft-guidance-on-cancer-trial-eligibility.